These figures pool every individual call made by Benchmark Co.'s analysts into a single sample — so a prolific analyst carries more weight than a low-volume one, exactly in proportion to the evidence available. All metrics are computed independently by 13Foresight from historical prices.
| Analyst | Our Rank | Stars | Success | Avg Return | vs S&P | Calls |
|---|---|---|---|---|---|---|
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Michael Rindos | #918 | ★★★ | 57% | +6.8% | -3.6% | 7 |
| Subash Chandra | #1152 | ★★★ | 62% | +10.1% | -0.5% | 29 |
| Mike Hickey | #1319 | ★★★ | 63% | +3.7% | -5.4% | 35 |
| Todd Brooks | #1430 | ★★★ | 45% | +1.3% | -4.1% | 20 |
| Bill Sutherland | #1926 | ★★ | 47% | -2.2% | -12.1% | 17 |
| Mickey Legg | #2185 | ★★ | 45% | -10.7% | -19.8% | 11 |
| Mark Zgutowicz | #2262 | ★★ | 29% | -3.5% | -8.3% | 28 |
| Reuben Garner | #2310 | ★★ | 28% | -10.6% | -21.5% | 18 |
| Yi Fu Lee | #2340 | ★ | 39% | +3.1% | -8.2% | 28 |
| Matthew Harrigan | #2431 | ★ | 40% | -10.1% | -18.5% | 30 |
| Robert Wasserman | #2465 | ★ | 39% | -10.4% | -26.6% | 28 |
| Fawne Jiang | #2494 | ★ | 28% | -5.5% | -18.6% | 36 |
| Ben Klieve | #2498 | ★ | 38% | -12.5% | -21.4% | 37 |
| Michael Albanese | #2503 | ★ | 33% | -14.0% | -30.4% | 30 |
| Daniel Kurnos | #2527 | ★ | 24% | -14.4% | -22.6% | 37 |
| Bruce Jackson | #2566 | ★ | 32% | -19.2% | -31.3% | 34 |
The 6 top-ranked analysts at Benchmark Co., the firm's full 3- and 5-year track record, and firm-vs-firm rankings across Wall Street. Everything below the top 6, plus 1- and 2-year history, stays free — Pro is what keeps this independent research running and the servers paid for.
Upgrade to ProDisclaimer: Firm-level performance is calculated independently by 13Foresight by pooling the historical calls of analysts associated with this firm, measured against market prices. It may be incomplete or delayed, is for research purposes only, and is not investment advice.